AIM
RXII

Acrospire Investment Management’s GALENA BIOPHARMA INC COM RXII Stock Holding History

Acrospire Investment Management’s Portfolio RXII Stock Details RXII Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-11,300
Closed -$5K – 2353
2016
Q2 		$5K Buy
+11,300
New +$5K ﹤0.01% 1877

Other funds holding RXII

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 28.54% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Acrospire Investment Management's RXII Position: Q3 2016 in Review

Acrospire Investment Management sold out of GALENA BIOPHARMA INC COM (RXII) in Q3 2016, closing a stake of 11,300 shares — an estimated $5K sold.

Acrospire Investment Management first reported a position in RXII in Q2 2016 and held it in 1 quarter. The position peaked at $5K in Q2 2016. 91 funds tracked by Wall St. Rank hold RXII as of Q3 2016.

  • Acrospire Investment Management reported no remaining GALENA BIOPHARMA INC COM position as of Q3 2016 after selling out during the quarter.
  • Acrospire Investment Management sold 11,300 GALENA BIOPHARMA INC COM shares in Q3 2016, an estimated $5K.
  • Acrospire Investment Management first reported a position in GALENA BIOPHARMA INC COM in Q2 2016 and held it in 1 quarter.
  • Acrospire Investment Management's GALENA BIOPHARMA INC COM position peaked at $5K in Q2 2016.
  • 91 funds tracked by Wall St. Rank held GALENA BIOPHARMA INC COM as of Q3 2016.

Based on Acrospire Investment Management's 13F filing for Q3 2016, filed 10 Nov 2016.